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Abstract  
The aim of the present work was to develop a minimally invasive system 
for the delivery of macromolecular drugs to the deep skin tissues, so called in-skin 
electroporation (IN-SKIN EP), using a microneedle (MN) electrode array.   
Fluorescein isothiocyanate (FITC)-dextran (FD-4: average molecular weight, 4.3 
kDa) was used as the model macromolecular drug.   MNs were arranged to puncture 
the skin barrier, the stratum corneum, and electrodes were used for EP so that a high 
electric field could be applied to skin tissues to promote viable skin delivery.  In 
vitro skin permeation experiments showed that IN-SKIN EP had a much higher skin 
penetration-enhancing effect for FD-4 than MN alone or ON-SKIN EP (conventional 
EP treatment), and that higher permeation was achieved by applying a higher voltage 
and longer pulse width of EP.  In addition, no marked skin irritation was observed by 
IN-SKIN EP, which was determined by the LDH leaching test.   
 These results suggest that IN-SKIN EP can be more effectively utilized as 
a potential skin delivery system of macromolecular drugs than MN alone and 
conventional ON-SKIN EP. 
  
Keywords: Microneedle; Electroporation; Microneedle electrode; Skin permeation; 
Skin irritation 
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1. Introduction 
The transdermal drug delivery system (TDDS) is a promising drug 
formulation that can not only be easily applied without the aid of medical staff 
compared to injectable formulations, but also offers several advantages, including the 
elimination of hepatic first-pass metabolism and severe adverse effects on the 
gastrointestinal tract of oral dosage forms (Jonathan Hadgraft, 1996; Asbill and 
Michniak, 2000); however, the stratum corneum, the primary barrier to the 
percutaneous absorption of drugs, has a key function against drug entry into the skin 
and the systemic circulation of TDDS. 
In order to overcome the formidable barrier of the stratum corneum, 
several physical means have been evaluated in addition to chemical enhancers to 
promote the skin permeation of drugs.  Among the physical means, a microneedle 
(MN) array can be an effective TDDS due to its advantage of providing a 
high-performance means to deliver therapeutic drugs through the skin barrier without 
causing marked skin damage (Kaushik et al., 2001; McAllister et al., 2003).  MN 
arrays can be made of polymers, metal, silicone rubber, polysaccharides and so on, 
and create new pores in the stratum corneum barrier to increase the permeation 
pathways of several drugs, including macromolecular drugs (Lin et al., 2001; 
Matriano et al., 2002; Martanto et al., 2004; Al-Qallaf and Das, 2009; Badran et al., 
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2009; Ding et al., 2009; Hafeli et al., 2009; Li et al., 2009); however, such new 
pathways do not always result in marked skin permeation.  We then combined the 
MN array with iontophoresis (MN-IP), which can be used to increase water flow, 
because electroosmosis takes place through the skin from the anode to the cathode in 
the iontophoresis system (Wu et al., 2007).  Electroosmosis may be used like a pump 
syringe for conventional injection (injection system consisting of a needle and pump 
syringe). 
Recently, another physical means, electroporation (EP), has been broadly 
applied to enhance the skin permeation of drugs.  EP involves the creation of tiny 
and transient aqueous pathways in the transcellular lipid region in the stratum 
corneum barrier.  EP application with a high-voltage electric pulse for a short period 
(millisecond order) results in the enhanced permeation of high molecular compounds 
(molecular weight of several hundreds to kilodaltons) through the skin (Medi and 
Singh, 2003; Fang et al., 2006; Tokumoto et al., 2006; Wong et al., 2006; Marra et al., 
2008; Gowrishankar et al., 2009; Sammeta et al., 2009; Xu et al., 2009).   
For both MN and EP, in spite of their different mechanisms, enhancement of 
the skin permeability of drugs is a result of the creation of new permeation pathways 
in the stratum corneum; however, the pathways do not always persist, so that the skin 
barrier function is recovered immediately after the pathways close up.  TEWL 
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(transepidermal water loss), as an index of permeability (Zhou et al., 2010), increases 
after the application of MN or EP and then decreases with time, which explains the 
recovery of skin barrier function.  To prolong the duration of new pathway (pore) 
openings, longer microneedles were investigated (Zhou et al., 2010) and electrolytes, 
such as calcium salt, were applied during EP application (Tokudome and Sugibayashi, 
2004) for MN and EP studies, respectively.   
To achieve a longer duration of pore opening for higher drug permeation 
in the present study, the mutual synergic action of MN and EP was considered to 
further increase skin permeation and the bioavailability of macromolecules.  The 
new present combination of MN and EP, so-called in-skin electroporation (IN-SKIN 
EP), was developed to combine the advantages of MN and EP.  An electrically 
active MN array was created as a device for the present IN-SKIN EP method.  Each 
MN could serve as a microelectrode for EP, which forms an electric field inside the 
skin barrier.  After IN-SKIN EP application, the drug is administered to the skin 
surface to be delivered into deeper skin tissues.  This system is different from 
conventional EP (ON-SKIN EP), where electrodes are applied just to the skin surface.  
IN-SKIN EP may facilitate the delivery of high molecular and hydrophilic 
compounds to deep skin tissues.  Furthermore, it affects only a small region of skin, 
not a wide area of skin by the MN electrode array; thus, IN-SKIN EP probably 
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increases skin permeability but with low skin irritation.  
In the present study, MN puncture of the skin was observed by scanning 
electron microscopy and confocal laser scanning microscopy.  Fluorescein 
isothiocyanate (FITC)-dextran (FD-4: average molecular weight, 4.3 kDa), which has 
poor skin permeation due to its high molecular weight and high hydrophilicity, was 
selected because it could be simply analyzed by a fluorescence spectrophotometer and 
morphologically observed by a confocal laser fluorescence microscope.  The effects 
of IN-SKIN EP were investigated by in vitro skin permeation experiments.  The 
intradermal distribution and skin permeation of FD-4 were determined.  In addition, 
a lactate dehydrogenase (LDH) leakage assay was carried out to evaluate skin damage 
after IN-SKIN EP pretreatment. 
 
2. Materials and methods 
2.1. Chemicals and animals 
FD-4 was purchased from Sigma Aldrich (St. Louis, MO, USA).  Other 
chemicals and reagents were of analytical grade and used without further purification. 
Male hairless rats (WBM/ILA-Ht, 7–9 weeks old) of approximately 
180–250 g were supplied either by the Life Science Research Center, Josai University 
(Sakado, Saitama, Japan) or Ishikawa Experimental Animal Laboratory (Fukaya, 
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Saitama, Japan).  They were kept at room temperature (25 ± 2°C) with a 12 h 
light–dark cycle (07:00–19:00 h).  All animal experiments were approved by the 
Institutional Animal Care and Use Committee of Josai University (Sakado, Saitama, 
Japan). 
The hairless rats were anesthetized by peritoneal injection of sodium 
pentobarbital (50 mg/kg) and hair on the abdomen was carefully shaved using an 
electric clipper.  Abdominal full-thickness skin was excised and adhering fat and 
connective tissues were carefully eliminated with a ring-ended forceps.  The excised 
skin was confirmed to have no damage, and was immediately used for the experiment. 
 
2.2. Application of IN-SKIN EP using an MN electrode-array  
The MN electrode-array for IN-SKIN EP, shown in Fig. 1, was prepared by 
modification of our previous method (Wu et al., 2007).  It was assembled using 9 
acupuncture needles (Haruhari, 1.5 mm; Taiho Medical Products Co., Ltd., Hiroshima, 
Japan), a silicone sheet (15 × 15 ×0.8 mm; Togawa Rubber Co., Ltd., Tokushima, 
Japan), polyvinyl chloride tape (thickness: 0.2 mm, safety extra low voltage: ~600 V) 
and a silver sheet (thickness: 0.1 mm), as shown in Fig. 1a.  Positive and negative 
electrodes were set with 4.0-mm spacing arranged alternately, as shown in Fig. 1b.  
Each needle was 400 μm long with a 28° angle beveled tip, and the base diameter of 
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the needle was approximately 200 μm, as shown in Fig. 1c.  Figure 1d shows a 
scanning electron micrograph of one MN tip.  In order to compare the effect of 
IN-SKIN EP with conventional ON-SKIN EP, the needle tips of the MN array were 
filed and struck with a file and hammer to make them obtuse, as shown in Fig. 1e.  
This obtuse tip needle array was used to apply EP at various points on the skin surface 
for ON-SKIN EP, so that a similar electric field could be created as a control 
experiment to research the IN-SKIN EP.   
 
Fig. 1. 
 
The excised skin was manually punctured using the MN electrode-array 
with vertical pressure of 3.53 N/cm2 for 10 s for IN-SKIN EP, whereas for ON-SKIN 
EP, the pressure was set at 0.10 N/cm2 to ensure that the needle tip did not puncture 
the skin.  This operation was performed on a balance to measure and control the 
pressure accurately.  A pulse generator (ECM 830 Electro Cell Manipulator; BTX, 
San Diego, CA, USA) was used to provide the square wave of EP (1 pulse/s), at 
50–200 V voltage and a pulse width of 10–100 ms. 
 
2.3. In vitro skin permeation experiments 
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The FD-4 skin permeation experiment was performed after pretreatment of 
excised hairless rat skin with IN-SKIN EP, ON-SKIN EP or MN alone.  The treated 
skin was mounted on vertical Franz-type diffusion cells (available diffusion area: 1.77 
cm2; volume of receiver cell: 6.0 mL) immediately after treatment, with the stratum 
corneum side facing the donor compartment and the dermal side facing the receiver 
compartment.  The test FD-4 solution (1.0 mg/mL, 1.0 mL) was added to the donor 
compartment, whereas phosphate-buffered saline (PBS, pH7.4, 6.0 mL) filled the 
receiver compartment.  The receiver solution was stirred by a magnetic bar to ensure 
adequate mixing to maintain the sink condition, and was kept at 32 °C with a water 
jacket. 
The solution was sampled at 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0 and 8.0 h 
after starting the permeation experiment, and an equal volume of fresh PBS was 
immediately added to keep the volume constant.  Intact full-thickness skin (no 
pretreatment) was also investigated for comparison. 
FD-4 concentration in the samples was determined using a 
fluorospectrophotometer (RF 5300 PC; Shimadzu, Kyoto, Japan) at an excitation 
wavelength of 495 nm and fluorescent emission wavelength of 515 nm (Wu et al., 
2006).  The calculated values for the cumulative amount of FD-4 that permeated the 
skin (µg/cm2) were plotted versus time. 
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2.4. Scanning electron micrographic observation 
Scanning electron microscopy (SEM, S-3000N; Hitachi, Tokyo, Japan) 
was used to observe the skin surface treated by IN-SKIN EP.  A skin specimen was 
mounted on an aluminum stub using double-sided adhesive tape and covered with 
gold using an ion sputter (E-1010; Hitachi), with the stratum corneum facing up.  
The samples were observed at 15 kV accelerating voltage, an approximately 20 mm 
working distance under a 30 Pa vacuum for skin samples. 
 
2.5. Fluorescence confocal microscopic observation 
Fluorescence confocal laser scanning was also performed for the excised 
hairless rat abdominal skin.  After the skin permeation experiment, the skin was 
taken from the diffusion cell and placed in a glass-bottomed dish (Iwaki; Asahi Glass 
Corp., Funabashi, Chiba, Japan), with the stratum corneum facing down, and FD-4 
distribution in the skin was observed using a fluorescence confocal laser scanning 
microscope (CSM, Fluoview FV1000; Olympus Corp.).  Fluorescence from the 
sample was excited by a 473 nm Hg laser (Rujirat Santipanichwong, 2009).  Images 
were collected using FluoView software (ver. 1.5; Olympus Corp.). 
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2.6. Confocal microscopic observation 
In order to measure the actual depth of pores made by MN alone or 
IN-SKIN EP, the interior of the skin was observed using a confocal laser scanning 
microscope (CLS, Vivascope1500, wavelength: 830 nm; Rochester, NY, USA).  
This instrument can be used to non-invasively observe the interior of tissues.  Tissue 
morphology up to a depth of 350 µm can be observed optically, with high sensitivity 
and specificity, correlating with histological sectioning (Altintas et al., 2008; Altintas 
et al., 2009).  The punctured areas of excised abdominal skin of hairless rats were 
observed immediately after puncture with MN alone or IN-SKIN EP. 
 
2.7. Measurement of lactate dehydrogenase (LDH) leakage from pretreated skin in 
vivo 
Hairless rats were anesthetized by s.c. injection of urethane (1.0 mg/kg), 
and hair on the abdomen was carefully removed using an electric clipper.  A glass 
cell cap was attached using adhesive (Aronalpha; Toagosei, Tokyo, Japan) after 
pretreatment with IN-SKIN EP.  Earle’s balanced salt solution (EBSS, 2.0 mL) was 
then added to the glass cell cap.  Whole solution was periodically collected from the 
glass cap cell, and the same volume of blank EBSS was added to keep the volume 
constant.  LDH leached from the stratum corneum side was determined by an assay 
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kit (Lactate Dehydrogenase Cytotoxicity Assay Kit; Cayman, MI, USA).  
Non-pretreated intact skin and stripped skin were also investigated for comparison.  
The stripped skin was made by stripping the stratum corneum 20 times with tape.  
All experiments were carried out in vivo.   
 
2. 8. Statistical analysis 
Statistical analysis was performed using the unpaired Student’s t-test.  
Significant difference was accepted at 0.05.  ANOVA was also applied in this study 
(Tokumoto et al., 2005). 
 
3. Results and discussion 
3.1. Effect of IN-SKIN EP pretreatment on the skin permeation of FD-4  
Figure 2 shows the time course of the cumulative amount of FD-4 that 
permeated skin pretreated with MN, ON-SKIN EP (200 V, 10 ms, 10 pulses) or 
IN-SKIN EP (200 V, 10 ms, 10 pulses).  The control experiment (no pretreatment) is 
also shown and was performed to establish a technique with reproducible results.  
Significant differences were found in the permeation profiles between control and 
pretreatment groups.  Little FD-4 (0.03 µg/cm2) permeated intact skin over 8 h, 
whereas MN and ON-SKIN EP pretreatment enhanced the permeability 
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approximately 7-fold (0.20 µg/cm2) and 20-fold (0.61 µg/cm2), respectively.  
Furthermore, IN-SKIN EP showed 140-fold (4.17 µg/cm2) permeability compared 
with the control permeation, suggesting a great synergistic effect of MN and EP on 
the skin permeation of FD-4.  These results, together with correlative results by 
conventional EP (Catherine Lombry et al., 2000; Tokudome and Sugibayashi, 2003) 
indicate that IN-SKIN EP resulted in higher drug permeability with a lower voltage or 
shorter pulse width of EP.  In addition, a higher skin penetration-enhancing effect 
could be obtained with IN-SKIN EP than with the previous MN-IP treatment (Wu et 
al., 2007), even though the permeation experiment for in vitro MN-IP treatment 
continued for 15 h.  
 
Fig. 2. 
 
Figure 3 shows scanning electron micrographs of intact skin (a) and skin 
pretreated with MN (b), ON-SKIN EP (200 V, 10 ms, 10 pulses) (c) and IN-SKIN EP 
(200 V, 10 ms, 10 pulses) (d).  The surface of skin pretreated with IN-SKIN EP was 
observed to assess the effect of IN-SKIN EP to produce a transport channel across the 
primary barrier, the stratum corneum, against drug entry to viable tissues.  The 
diameter of the newly produced transport channels was measured horizontally and 
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vertically, and their average size was used as an index of channel size.  The average 
diameter of the channel produced by MN alone was 77.65 μm (Fig. 3b), and that by 
ON-SKIN EP was 168.83 μm (Fig. 3c), but no distinct channel was produced by 
ON-SKIN EP.  The average diameter of the channel with IN-SKIN EP pretreatment 
was 166.20 μm (Fig. 3d).  IN-SKIN EP produced the largest and deepest pore 
channels in skin, among the methods in the present study, and these channels would 
be new effective permeation pathways for chemical compounds, even 
macromolecules.   
 
Fig. 3. 
 
Intradermal distribution of FD-4 after IN-SKIN EP pretreatment was also 
investigated using a confocal fluorescein microscope (CSM).  Figure 4 shows 
fluorescein CSM images of skin sections.  It is known from the present in vitro skin 
permeation experiments that the cumulative amount of FD-4 permeated was very 
limited in intact skin (Fig. 2).  Correspondingly, in Fig. 4a, the average depth of 
fluorescent part is 20-30 μm, so it can be considered that FD-4 is only distributed on 
the skin and in the stratum corneum but not permeating to the deep part.  In the skin 
pretreated with MN (Fig. 4b), the arrow shows puncture site by MN, where the 
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fluorescence front was about 60 μm depth.  In ON-SKIN EP (EP condition: 200 V, 
10 ms, 10 pulses) (Fig. 4c), the fluorescence was distributed averagely deeper than 
intact skin or MN pretreatment.  The thickness of green fluorescence in Fig. 4a-c 
was well correlated to the skin permeation of FD-4 as shown in Fig. 2.  Although 
only a little difference was found among the picture in Fig. 4a-c, much deeper green 
trails could be clearly observed through the transport channel in skin pretreated with 
IN-SKIN EP (EP condition: 200 V, 10 ms, 10 pulses) (Fig. 4d).  FD-4 was 
effectively delivered to the deep part of skin in IN-SKIN EP.  
 
Fig. 4. 
 
  The pore channel below the skin surface produced by MN alone and 
IN-SKIN EP was observed by a confocal microscope.  A series of pictures was taken 
from the surface to the deep part of the skin to analyze the depth of pores made by 
MN alone or IN-SKIN EP.  Figure 5a–c shows skin pores (arrow) of 0.00, 10.96, and 
65.85 μm depth, respectively, with MN alone.  No pore was found in the depth of 
65.85 μm (dotted line arrow).  Although the MN electrode was 400 µm long (Fig. 
1c), pore depth was less than 1/6 the full length of the MN, probably due to skin 
elasticity.  Hairless rat skin consists of three layers: stratum corneum (approximately 
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0–10 µm), viable epidermis (approximately 60–90 μm) and dermis (>90 μm) 
(Bouclier et al., 1987).  Thus, MN tips reached the viable epidermis and bypassed 
the stratum corneum.  The holes punctured by MN therefore act as a permeation 
pathway for high molecular compounds.  
The pores made by IN-SKIN EP were also observed.  Figure 5d–f shows a 
similar set of images for IN-SKIN EP pretreatment to Fig. 5a–c for MN alone.  EP 
conditions were 200 V, 10 msec and 10 pulses.  Compared to Fig. 5a–c, the pores 
made by IN-SKIN EP were much larger and deeper.  Limited by the quality of the 
images, data were collected until a depth of 79.84 µm (Fig. 5f).  The pore could still 
be observed in the recorded depth.  These data show a coincidence in depth with Fig. 
4b and d.  In addition, the zone of the puncture periphery, which was a circular 
region of approximately 100-μm diameter, was dark in the images.  This could be 
considered a type of change in skin tissues, such as localized transport regions (LTR), 
as well as the Joule heat effect.  Although evidence of the creation of these LTRs is 
still indirect in the present study, this zone is also considered as the effect of EP and 
acts as an important part of drug permeation (Pliquett et al., 1996; Prausnitz, 1996; 
Zewert et al., 1999; Denet et al., 2004).   
 
Fig. 5. 
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3. 2. Effect of voltage and pulse width on IN-SKIN EP treatment 
Figure 6 shows the effect of the application voltage and pulse width of EP 
on the cumulative amounts of FD-4 that permeated skin pretreated by IN-SKIN EP 
(over 8 h).  Voltage, pulse width and the number of pulses are the three most 
important parameters of the EP effect on skin permeation (Sharma et al., 1999).  In 
this study, the effective application period of IN-SKIN EP was fixed to 10 s, and the 
square wave pulse was applied at 1 pulse/s, so the number of pulses became 10.  
When the voltage condition was 0, 50, 100 or 150 V under a pulse width of 10 ms, the 
cumulative amount of FD-4 skin permeation over 8 h was 0.20 ± 0.05, 0.23 ± 0.03, 
0.64 ± 0.19 or 1.35 ± 0.91 µg/cm2, respectively.  When the pulse width was fixed to 
50 ms and the voltage condition was 50, 100 or 150 V, the cumulative amount over 8 
h was 0.33 ± 0.03, 0.81 ± 0.13 or 1.96 ± 0.64 µg/cm2, respectively.  Based on these 
data, the cumulative amount over 8 h increased with the increase in applied voltage 
with convex downward.  When the voltage was increased to 200 V, the cumulative 
amount increased steeply.  When the voltage condition was 50 or 100 V at a pulse 
width of 100 ms, the cumulative amount over 8 h was 0.68 ± 0.18 or 3.00 ± 0.12 
µg/cm2, respectively.  Increasing the pulse width to 100 ms is therefore an effective 
way to achieve a high cumulative permeation drug amount, even at a lower voltage.  
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Although either the voltage or pulse width could markedly contribute to FD-4 
permeability through excised hairless rat skin, 200 V and 10 ms pulse width showed 
the highest FD-4 permeation among the conditions evaluated in this study.  No data 
are shown for severe IN-SKIN EP conditions, such as high voltage (> 200 V) or long 
pulse width (> 100 ms), since the sink condition could not be maintained in the 
receiver solution over 8 h due to the extremely high skin permeation of FD-4.   
Although the effect of molecular weight of a drug or compound is always 
considered an important factor in the research of transdermal drug delivery, FD-4 was 
used as a model compound to evaluate a new combination of MN and EP.  Based on 
the results in the present study, other model compounds with larger molecular weight 
will also be investigated in the following study.   
 
Fig. 6. 
 
3.3. Influence of IN-SKIN EP on lactate dehydrogenase (LDH) leaching from skin 
EP application was found to increase tissue temperature due to Joule heating 
(Becker and Kuznetsov, 2007).  It was considered from the present SEM images that 
a certain level of scorching was found in pores punctured by IN-SKIN EP.  
Cutaneous cells may be damaged when the skin is punctured by IN-SKIN EP.  In 
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order to estimate the irritation caused by IN-SKIN EP, LDH leaching from the skin 
was determined.  The LDH leaching was used to assess skin viability (Messager et 
al., 2003; Wu et al., 2006) in order to evaluate the safety of different physical 
enhancing methods.  Two strong EP conditions (200 V, 10 ms, 10 pulses and 100 V, 
100 ms, 10 pulses) were evaluated.  Stripped skin was also evaluated for comparison.  
Figure 7 shows the cumulative amount of LDH leakage from the skin surface over 1, 
4 and 8 h after pretreatment.  The cumulative amount of LDH leaching from stripped 
skin was 6.6 times that of intact skin over 8 h.  In contrast, no significant difference 
was found between intact skin and either of the pretreatment conditions; therefore, in 
the present study, it can be concluded that IN-SKIN EP could create a novel 
permeation route to enhance penetration with little damage to skin cells.  
Histological investigation is necessary to evaluate the safety of the IN-SKIN EP 
method in detail. 
 
Fig. 7. 
 
4. Conclusions 
In order to deliver macromolecules through skin, it is important to surmount 
the stratum corneum barrier to increase permeability.  To address this challenge, a 
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novel IN-SKIN EP was developed in this research.  From the present results of the in 
vitro skin permeation of FD-4, it was concluded that treatment with MN or ON-SKIN 
EP alone increased the permeation of FD-4 through excised hairless rat skin, and 
IN-SKIN EP further increased skin permeation, which was considered a great 
synergistic effect of MN and ON-SKIN EP.  In particular, higher permeation was 
achieved when applying higher voltage and longer pulse width EP.  The skin 
distribution of FD-4 indicated the centrality of the EP application site in this system.  
In the present study, the low irritation of IN-SKIN EP could be concluded from the 
LDH experiment. 
In conclusion, IN-SKIN EP can effectively deliver high molecular and 
hydrophilic drugs.  Not only drug solutions but also the topical formulations, such as 
gel, ointment or a patch can be applied after pretreatment with IN-SKIN EP, and could 
be more convenient for clinical application.   
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Figure legends 
Fig. 1.  Schematic illustration of MN electrode-array made by acupuncture needles.  
a) Top view, b) Back view, c) Side view, d) Microphotograph of needle tip, e) 
Microphotograph of obtuse needle tip for ON-SKIN EP. 
 
Fig. 2.  Time course of the cumulative amount of FD-4 that permeated intact skin, 
skin treated with MN alone, skin treated with ON-SKIN EP and skin treated with 
IN-SKIN EP.  Symbols: ◇, no pretreatment (intact skin); ☐, MN alone; △, 
ON-SKIN EP (200 V, 10 ms, 10 pulses); ●, IN-SKIN EP (200 V, 10 ms, 10 pulses).  
Each data point represents the mean ± S.E. of four or five experiments. 
 
Fig. 3.  SEM microphotograph of pores on the skin surface after pretreatment.  a) 
Intact skin, b) MN alone, c) ON-SKIN EP (200 V, 10 ms, 10 pulses), d) IN-SKIN EP 
(200 V, 10 ms, 10 pulses). 
 
Fig. 4.  Fluorescence confocal laser scanning microscopy (CSM) images of FD-4 
distribution after 8 h permeating intact and pretreated skin.  a) Intact skin, b) MN 
only, c) ON-SKIN EP (200 V, 10 ms, 10 pulses), d) IN-SKIN EP (200 V, 10 ms, 10 
pulses). 
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Fig. 5.  Confocal laser scanning microscopy (CLS) images in the puncture direction 
of the pore punctured by MN alone (a–c) and IN-SKIN EP (d-f).  Depth: a) 0.00 µm, 
b) 10.96 µm, c) 65.85 µm, d) 0.00 µm, e) 49.90 µm, f) 79.84 µm. 
 
Fig. 6.  Effect of pulse width and voltage of EP on the time course of the cumulative 
amount of FD-4 that permeated hairless rat skin.  Symbols: ◆, 10 ms; ■, 50 ms; ▲, 
100ms.  Each data point represents the mean ± S.E. of four or five experiments. 
 
Fig. 7.  Effect of different pretreatments on LDH leaching from the skin surface.  
Each point represents the mean ± S.E. of three or four experiments.  (*: < 0.05; **: < 
0.01)  Intact skin,  MN-EP (200 V, 10 ms),  MN-EP (100 V, 100 ms) and 
 Stripped skin. 
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